Monitoring of Minimal Residual Disease in NPM1-Mutated Acute Myeloid Leukemia: A Study From the German-Austrian Acute Myeloid Leukemia Study Group
J Krönke, RF Schlenk, KO Jensen… - Journal of Clinical …, 2011 - ascopubs.org
Purpose To evaluate the prognostic value of minimal residual disease (MRD) in patients
with acute myeloid leukemia (AML) with NPM1 mutation (NPM1 mut). Patients and Method …
with acute myeloid leukemia (AML) with NPM1 mutation (NPM1 mut). Patients and Method …
FOXM1 in cancer: interactions and vulnerabilities
AL Gartel - Cancer research, 2017 - AACR
FOXM1 is a transcription factor of the Forkhead family that is required for cell proliferation of
normal cells. However, FOXM1 is repeatedly overexpressed in a variety of human cancers …
normal cells. However, FOXM1 is repeatedly overexpressed in a variety of human cancers …
Incidence and Prognostic Influence of DNMT3A Mutations in Acute Myeloid Leukemia
F Thol, F Damm, A Lüdeking, C Winschel… - Journal of Clinical …, 2011 - ascopubs.org
Purpose To study the incidence and prognostic impact of mutations in DNA
methyltransferase 3A (DNMT3A) in patients with acute myeloid leukemia. Patients and …
methyltransferase 3A (DNMT3A) in patients with acute myeloid leukemia. Patients and …
[HTML][HTML] Allogeneic stem cell transplantation for acute myeloid leukemia: who, when, and how?
Although the majority of patients with acute myeloid leukemia (AML) treated with intensive
chemotherapy achieve a complete remission (CR), many are destined to relapse if treated …
chemotherapy achieve a complete remission (CR), many are destined to relapse if treated …
Real-Time Quantitative Polymerase Chain Reaction Detection of Minimal Residual Disease by Standardized WT1 Assay to Enhance Risk Stratification in Acute …
D Cilloni, A Renneville, F Hermitte, RK Hills… - Journal of Clinical …, 2009 - ascopubs.org
Purpose Risk stratification in acute myeloid leukemia (AML) is currently based on
pretreatment characteristics. It remains to be established whether relapse risk can be better …
pretreatment characteristics. It remains to be established whether relapse risk can be better …
Drug therapy for acute myeloid leukemia
MS Tallman, DG Gilliland, JM Rowe - Blood, 2005 - ashpublications.org
Although improvement in outcomes has occurred in younger adults with acute myeloid
leukemia (AML) during the past 4 decades, progress in older adults has been much less …
leukemia (AML) during the past 4 decades, progress in older adults has been much less …
Small-molecule inhibition of the acyl-lysine reader ENL as a strategy against acute myeloid leukemia
The chromatin reader eleven–nineteen leukemia (ENL) has been identified as a critical
dependency in acute myeloid leukemia (AML), but its therapeutic potential remains unclear …
dependency in acute myeloid leukemia (AML), but its therapeutic potential remains unclear …
FLT3 as a therapeutic target in AML: still challenging after all these years
Mutations within the FMS-like tyrosine kinase 3 (FLT3) gene on chromosome 13q12 have
been detected in up to 35% of acute myeloid leukemia (AML) patients and represent one of …
been detected in up to 35% of acute myeloid leukemia (AML) patients and represent one of …
Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype
S Schnittger, C Schoch, W Kern, C Mecucci, C Tschulik… - Blood, 2005 - ashpublications.org
Nucleophosmin (NPM1) exon-12 gene mutations are the hallmark of a large acute
myelogenous leukemia (AML) subgroup with normal karyotype, but their prognostic value in …
myelogenous leukemia (AML) subgroup with normal karyotype, but their prognostic value in …
Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression …
RGW Verhaak, CS Goudswaard, W Van Putten, MA Bijl… - Blood, 2005 - ashpublications.org
Mutations in nucleophosmin NPM1 are the most frequent acquired molecular abnormalities
in acute myeloid leukemia (AML). We determined the NPM1 mutation status in a clinically …
in acute myeloid leukemia (AML). We determined the NPM1 mutation status in a clinically …